SpA: ACR2025 Topic Panel Save

A focused conversation on the latest in SpA from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping SpA practice right now. Panelists: Drs. Antoni Chan, Marina Magrey, Atul Deodhar and Jack Cush. Abstracts discussed: 1434 (Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort); 0854: (The Assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study); LB09 (Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis); 1444 (Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis); 1435 (Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study); and 0886 (A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis)